Jörg Täubel, Ulrike Lorch, Simon Coates, Sara Fernandes, Paul Foley, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl Confirmation of the Cardiac…
Month: February 2018
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
The WHO considers infertility a global public health issue affecting 186 million people, and only 1 in 4 ART treatments…
ObsEva Investor Conference Call
ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018
Geneva, Switzerland and Boston, MA – February 23, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
LEERINK Partners 7th Annual Global Healthcare Conference
ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018
Geneva, Switzerland and Boston, MA – February 7, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons
Geneva, Switzerland and Boston, MA – February 1, 2018– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
